Toll-like Receptor 2 Facilitates Oxidative Damage-Induced Retinal Degeneration.

2-(ω-Carboxyethyl) pyrrole C3 C5b-C9 Complement Membrane Attack Complex (MAC) NaIO3 Toll-like receptor 2 (TLR2) age-related macular degeneration (AMD) oxidative stress retinal degeneration

Journal

Cell reports
ISSN: 2211-1247
Titre abrégé: Cell Rep
Pays: United States
ID NLM: 101573691

Informations de publication

Date de publication:
18 02 2020
Historique:
received: 26 04 2019
revised: 18 09 2019
accepted: 21 01 2020
entrez: 21 2 2020
pubmed: 23 2 2020
medline: 10 3 2021
Statut: ppublish

Résumé

Retinal degeneration is a form of neurodegenerative disease and is the leading cause of vision loss globally. The Toll-like receptors (TLRs) are primary components of the innate immune system involved in signal transduction. Here we show that TLR2 induces complement factors C3 and CFB, the common and rate-limiting factors of the alternative pathway in both retinal pigment epithelial (RPE) cells and mononuclear phagocytes. Neutralization of TLR2 reduces opsonizing fragments of C3 in the outer retina and protects photoreceptor neurons from oxidative stress-induced degeneration. TLR2 deficiency also preserves tight junction expression and promotes RPE resistance to fragmentation. Finally, oxidative stress-induced formation of the terminal complement membrane attack complex and Iba1+ cell infiltration are strikingly inhibited in the TLR2-deficient retina. Our data directly implicate TLR2 as a mediator of retinal degeneration in response to oxidative stress and present TLR2 as a bridge between oxidative damage and complement-mediated retinal pathology.

Identifiants

pubmed: 32075760
pii: S2211-1247(20)30089-9
doi: 10.1016/j.celrep.2020.01.064
pmc: PMC7179253
mid: NIHMS1563624
pii:
doi:

Substances chimiques

TLR2 protein, human 0
Tlr2 protein, mouse 0
Toll-Like Receptor 2 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2209-2224.e5

Subventions

Organisme : NEI NIH HHS
ID : P30 EY011373
Pays : United States
Organisme : NEI NIH HHS
ID : P30 EY025580
Pays : United States
Organisme : NEI NIH HHS
ID : R01 EY016813
Pays : United States

Informations de copyright

Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Interests The authors declare no competing interests.

Auteurs

Kelly Mulfaul (K)

Department Clinical Medicine, School of Medicine, Trinity College Dublin, Dublin, Ireland.

Ema Ozaki (E)

Department Clinical Medicine, School of Medicine, Trinity College Dublin, Dublin, Ireland.

Nilisha Fernando (N)

The John Curtin School of Medical Research, The Australian National University, Canberra, ACT, Australia.

Kiva Brennan (K)

Department Clinical Medicine, School of Medicine, Trinity College Dublin, Dublin, Ireland.

Kathleen R Chirco (KR)

Institute for Vision Research, University of Iowa, Iowa City, IA, USA.

Emma Connolly (E)

Department Clinical Medicine, School of Medicine, Trinity College Dublin, Dublin, Ireland.

Chris Greene (C)

Smurfit Institute of Genetics, Trinity College Dublin, Dublin, Ireland.

Arvydas Maminishkis (A)

National Eye Institute, National Institutes of Health, Bethesda, MD, USA.

Robert G Salomon (RG)

Department of Chemistry, Case Western Reserve University, Cleveland, OH, USA.

Mikhail Linetsky (M)

Department of Chemistry, Case Western Reserve University, Cleveland, OH, USA.

Riccardo Natoli (R)

The John Curtin School of Medical Research, The Australian National University, Canberra, ACT, Australia; The ANU Medical School, The Australian National University, Canberra, ACT, Australia.

Robert F Mullins (RF)

Institute for Vision Research, University of Iowa, Iowa City, IA, USA.

Matthew Campbell (M)

Smurfit Institute of Genetics, Trinity College Dublin, Dublin, Ireland.

Sarah L Doyle (SL)

Department Clinical Medicine, School of Medicine, Trinity College Dublin, Dublin, Ireland; Trinity College Institute of Neuroscience (TCIN), TCD, Dublin 2, Ireland; The National Children's Research Centre, Our Lady's Hospital Crumlin, Dublin 12, Ireland. Electronic address: sarah.doyle@tcd.ie.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH